Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Compass Therapeutics (CMPX) EBIT Margin (2024)

Compass Therapeutics (CMPX) has disclosed EBIT Margin for 1 consecutive years, with 1770.0% as the latest value for Q2 2024.

  • Quarterly EBIT Margin changed N/A to 1770.0% in Q2 2024 from the year-ago period, while the trailing twelve-month figure was 7273.41% through Mar 2025, changed N/A year-over-year, with the annual reading at 6661.76% for FY2024, N/A changed from the prior year.
  • EBIT Margin hit 1770.0% in Q2 2024 for Compass Therapeutics.
  • In the past five years, EBIT Margin ranged from a high of 1770.0% in Q2 2024 to a low of 1770.0% in Q2 2024.